Description
Estradiol Transdermal System Patch is available by prescription only. Go ahead and place your purchase. After making payment, we will ensure that a valid prescription is received from your prescriber
Drug Label Highlights
These highlights do not include all the information needed to use ESTRADIOL TRANSDERMAL SYSTEM CONTINUOUS DELIVERY (ONCE-WEEKLY) safely and effectively. See full prescribing information for ESTRADIOL TRANSDERMAL SYSTEM CONTINUOUS DELIVERY (ONCE-WEEKLY).
ESTRADIOL transdermal system continuous delivery (once-weekly)
Initial U.S. Approval: 1975
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, and BREAST CANCER
See full prescribing information for complete boxed warning.
Estrogen-Alone Therapy
Estrogen Plus Progestin Therapy
Indications And Usage
Estradiol transdermal system continuous delivery (once-weekly) is an estrogen indicated for:
Limitations of Use
When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products.
Limitations of Use
When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.
Dosage And Administration
Dosage Forms And Strengths
Contraindications
Warnings And Precautions
- Estrogens increase the risk of gallbladder disease (5.4)
- Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs (5.5, 5.6, 5.9, 5.10)
- Monitor thyroid function in women on thyroid hormone replacement therapy (5.11, 5.18)
- Estrogens increase the risk of gallbladder disease (5.4)
- Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs (5.5, 5.6, 5.9, 5.10)
- Monitor thyroid function in women on thyroid hormone replacement therapy (5.11, 5.18)
Adverse Reactions
The most common adverse reactions (≥ 10 percent) with estradiol transdermal system continuous delivery (once-weekly) are: breast pain, upper respiratory tract infections, headaches, abdominal pain, pain, and edema. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interactions
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 6/2025
DailyMed highlights last updated: 2026-06-24 23:17:40









Reviews
There are no reviews yet.